R&D & BIOTECHNOLOGY PLATFORM

Translational Peptide Discovery & Advanced Venom Biotechnology

Bridging world-class molecular science and proteomics with novel drug discovery, advanced dermocosmetics, and partner-ready data assets.

At Venomers (AKT), our R&D division is the core engine of innovation. Leveraging state-of-the-art analytical infrastructure, advanced protein purification platforms (FPLC/HPLC), and an extensive international academic network, we manage the complete value chain—from raw scorpion venom extraction to targeted therapeutic bio-peptides, specialized cutaneous formulations, and commercial-ready scientific dossiers (Partner-Ready Packages).

Submit B2B R&D Proposal

Target Readiness

TRL 4

Technology Readiness Level

Oncology & Bio-Peptide Screening
Academic Output

2+

Peer-Reviewed Papers

Nature Portfolio & MDPI Journals
Quality Assurance

100%

Bio-Standardization

Proteomics & GMP Protocols
Global Footprint

4 Hubs

Geostrategic R&D Network

Iran, Germany, Turkey, Oman

4-Stage Analytical Workflow & Proteomics Suite

End-to-End Analytical Workflow: From Crude Venom to Validated Bio-Assets

To eliminate batch-to-batch variability and streamline venom-derived R&D, Venomers employs a rigorous 4-stage analytical framework. Every biological batch passes sequentially through quantitative protein measurement, chromatographic fractionation, mass spectrometry fingerprinting, and functional bio-testing—delivering fully documented, research-ready data packages for our B2B partners.

In venom-derived biopharmaceuticals and target discovery, batch variability and uncharacterized complex mixtures pose major bottlenecks for CROs and pharmaceutical developers. At Venomers (AKT), our analytical workflows operate under strict Standard Operating Procedures (SOPs) designed to deliver fully documented molecular data packages from controlled biological collection to cryo-packaging.

We do not merely supply raw materials; we provide B2B partners with batch-coded chromatographic profiles, mass spectrometry fingerprints, and standardized fraction packages—laying a reliable foundation for ion-channel pharmacology, oncology screening, and advanced cutaneous formulations.

SOP-Driven Batch Analytical Consistency

3–7 kDa Low-MW Neurotoxin Resolution

Multi-Tier Proteomic & Spectroscopic Access

Venomers controlled biological processing and analytical facility

STAGE 01 — QUANTITATIVE ENTRY

01. Quantitative & Electrophoretic Profiling

The entry point of our analytical workflow. We establish baseline protein concentration using standardized Kjeldahl total nitrogen %, Bradford, and BCA quantification assays. Full molecular weight distribution (ranging from 2 to 250 kDa) is visualized via SDS-PAGE and Tricine SDS-PAGE gel electrophoresis to confirm structural integrity.

B2B Value Proposition

Precise total protein dosing and batch integrity verification prior to screening.

Tricine SDS-PAGE (2–250 kDa) Bradford & BCA Quantification Kjeldahl Total Nitrogen % Batch Baseline Verification

STAGE 02 — PURIFICATION & SEPARATION

02. Chromatographic Profiling & Fractionation

Crude venom samples undergo Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC-PDA) and FPLC fractionation. This step maps peak profiles, calculates peak purity indices, and separates complex venom into isolated peptide fraction libraries for targeted research.

B2B Value Proposition

Customizable fraction isolation allowing partners to test specific active peaks rather than crude mixtures.

RP-HPLC-PDA FPLC Fractionation Peak Purity Indexing Custom Fraction Libraries

STAGE 03 — MOLECULAR FINGERPRINTING

03. Mass Spectrometry & Venomics Fingerprinting

High-resolution molecular mass determination using MALDI-TOF MS (Applied Biosystems Sciex 4800) and LC-MS / LC-ESI-QTOF platforms. This stage creates intact mass fingerprints, precisely resolving low-MW neurotoxin peptides (3–7 kDa) and mapping the venom proteome.

B2B Value Proposition

Unambiguous molecular identity and batch-coded data packages that eliminate species substitution risk.

MALDI-TOF MS (Sciex 4800) LC-MS / LC-ESI-QTOF Mass Fingerprinting (3–7 kDa) Proteomic Mapping

STAGE 04 — FUNCTIONAL & STRUCTURAL VALIDATION

04. Bioassays & Specialized Structural Testing

Functional and structural validation using preliminary in-vitro cytotoxicity assays (MTT, IC50 determination). Supported by Raman spectroscopy for protein backbone identification and GC-MS for volatile lipid and scorpion oil profiling.

B2B Value Proposition

Data-driven candidate ranking and early bio-activity insights for oncology, antimicrobial, and formulation R&D.

In-Vitro IC50 Screening Raman Spectroscopy GC-MS Lipid Analysis Candidate Prioritization Data

Traceability & Analytical Transparency Dashboard

Batch-Coded Traceability

Every sample carries a unique batch ID tied to species origin, collection date, cryo-storage log, and complete analytical records.

Certificate of Analysis (CoA)

Deliveries are accompanied by a comprehensive technical dossier featuring raw HPLC chromatograms, MS peak tables, and protein assay data.

Verified Cold-Chain Logistics

Stored in -80°C ultra-low freezers and shipped via liquid nitrogen (-196°C) or dry ice to preserve structural integrity and bio-activity.

Request R&D & Custom Analytical Services

Evidence-Based Discovery & Academic Rigor

Scientific Research & Active R&D Portfolio

Development of venom-derived pharmaceuticals and peptides requires a formidable research foundation and validated methodology. Venomers, in collaboration with leading international and national universities and research centers, establishes its R&D platform on peer-reviewed scientific publications, rigorous preclinical research, and high standards of molecular transparency.

Featured Peer-Reviewed Publications

MDPI Toxins Published · 2022 Peer-Reviewed · Open Access

Mass-Spectrometry-Based Lipidome & Proteome Profiling of Hottentotta saulcyi Venom

Authors: Parviz Ghezellou, Kevin Jakob, Javad Atashi , Alireza Ghassempour, Bernhard Spengler

100,000 Res Orbitrap MS Resolution

~1.2% Mass Venom Lipidome Yield

Na⁺ / K⁺ Blocker Ion Channel Peptides

Key Discoveries & Analytical Findings

High-Res Mass Spec: Complete Orbitrap MS profiling of H. saulcyi venom proteome.
Ion Channel Blockers: Low-MW Na⁺ and K⁺ channel blocker peptides & metalloproteinases.
First Venom Lipidome: ~1.2% dry weight lipid composition (phospholipids, ceramides).

MDPI Toxins MALDI-TOF & Orbitrap MS Giessen Univ. Joint Lab

DOI: 10.3390/toxins14060370 MDPI Page

Nature Scientific Reports · 2025 Nature Portfolio · Peer-Reviewed

Proteomic Profiling of Scorpion Venom Proteins from Hottentotta saulcyi & Odontobuthus doriae: Biomedical Applications & Mechanistic Insights

Authors: Javad Atashi , Shekoufeh Hatami, Roghayyeh Aghaei, Amin Safaei, Marjan Jafari, Dr. Mohammad Zarei , Dr. Adel Abdollahnia , Dr. med. Thomas Flietner , Monika Joanna Gawron, Fatemeh Atashi, Dr. Mohammad Hossein Morowvat

3–7 kDa Low-MW Neurotoxin Peptides

MCF-7 & HepG2 Preclinical IC50 Cancer Screening

SUMS & MPDRI Multidisciplinary R&D Joint Venture

Key Discoveries & Preclinical Insights

Comparative Proteomics: Molecular mass mapping of H. saulcyi & O. doriae venom proteins.
Preclinical Bioactivity: Selective cytotoxicity & IC50 assays on MCF-7 breast & HepG2 liver cancer cell lines.
Biomedical Applications: Validated antibacterial & antimicrobial peptide fractions.

Nature Scientific Reports (2025) Low-MW Neurotoxins (3–7 kDa) Oncology Bioactivity

DOI: 10.1038/s41598-025-31108-9 Nature Journal Page

Ongoing Preclinical & R&D Pipelines

PRECLINICAL IN-VITRO · ONCOLOGY

Targeted Anti-Cancer Efficacy & Cytotoxicity Screening

Institutional Partners Shiraz University of Medical Sciences (SUMS) & MPDRI Shahid Beheshti University

Selective Cytotoxicity Screening: In-vitro IC50 determination of isolated scorpion peptide fractions against Breast Cancer (MCF-7), Liver Cancer (HepG2), and Skin Cancer cell lines.
Targeted Lead Selection: Identifying high-selectivity therapeutic lead candidates while guaranteeing minimal toxicity to normal cell lines.

In-Vitro IC50 Assays Breast & Liver Models Ion-Channel Targets Selectivity Profiling

ACTIVE CONTRACT · SPECIES PURITY

Biosystematics, Morphometrics & Molecular Identification

Institutional Partners Zabol University Research Institute (Lead: Dr. Hossein Barahoei ) & HUMS

Biosystematic Expeditions: Field campaigns and morphometric/molecular profiling of Buthidae scorpion fauna across Fars Province and Southern Iran.
100% Species Purity: Rigorous biological identity validation during venom extraction, eliminating inter-species batch variations.

Morphometrics 100% Species Purity Field Expeditions Taxonomic QC

FORMULATION & FDA HUB · CUTANEOUS

Translational Bio-Peptides & Cutaneous Formulation

Institutional Partners Biotechnology Growth Center (SUMS) & Iran FDA Reference Laboratory Hub

Non-Injectable Bio-Peptides: Development of advanced Botox-like peptide gels for topical anti-aging and facial rejuvenation.
GC-MS Scorpion Oil & Chitosan: Instrumental analysis of purified GAZHDIN scorpion oil for topical formulations, and high-purity chitosan extraction from scorpion exuviae.

Botox-Like Bio-Gel GC-MS Scorpion Oil Chitosan Extraction Iran FDA Verified

Global Academic & Institutional Research Network

International Partner Giessen, Germany 🇩🇪

Justus Liebig University Giessen

Advanced chemical spectrometry, Orbitrap proteomic profiling, and mass spectrometry analysis of scorpion venom components.

Orbitrap Proteomics Mass Spectrometry

International Partner Vienna, Austria 🇦🇹

Medical University of Vienna

Collaboration in peptide peptidomics, opioid receptor binding assays, and medicinal chemistry R&D.

Peptidomics Opioid Receptor Assays

National HQ & Preclinical Hub Shiraz, Iran 🇮🇷

Shiraz University of Medical Sciences

School of Pharmacy & Biotech Growth Center serving as R&D headquarters for preclinical cell line cytotoxicity testing.

R&D Headquarters Cytotoxicity Hub

National Partner Tehran, Iran 🇮🇷

Shahid Beheshti University (MPDRI)

Medicinal Plants and Drugs Research Institute collaborating on instrumental proteomic analysis and biological efficacy.

Proteomic Analysis Biological Efficacy

National Partner Zabol & HUMS, Iran 🇮🇷

Zabol University & HUMS

Formal research agreements for regional species bio-mapping, biosystematics, and skin cancer screening.

Species Bio-Mapping Biosystematics